June 28, 2010 / 5:04 AM / 7 years ago

India's Sun Pharma to stop selling Eloxatin generic

MUMBAI, June 28 (Reuters) - Sun Pharmaceutical Industries (SUN.BO) will stop selling generic version of Sanofi-Aventis’ (SASY.PA) cancer drug Eloxatin in the United States after June 30 following a court order, the Indian drugmaker said.

In April, Sanofi-Aventis settled a patent law suit over Eloxatin with additional drugmakers, stopping them from selling their generic versions in the United States from June 30 until August 2012. [ID:nLDE635050]

Caraco Pharmaceutical Laboratories Ltd CPD.A, a unit of Sun Pharmaceutical, had said in March it had launched the generic version of anti-cancer drug oxaliplatin in injection form in the United States. [ID:nSGE62B07M] (Reporting by Sumeet Chatterjee)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below